While high recurrence rates due to acquired tumor resistance present a challenge to Epidermal Growth Factor Receptor inhibition, combination therapies, particularly with PI3K inhibitors, have shown improved treatment responses in pHGG patients.[38]. The gene discussed is EGFR; the disease is neoplasm.